Our lead drug candidate, tipifarnib, is an inhibitor of protein farnesylation, a key cell signaling process implicated in cancer initiation and development. Tipifarnib has been studied in more than 5,000 patients and has demonstrated anti-cancer activity in certain patient subsets and a well-established safety profile. Clinical and preclinical data suggest that in the right therapeutic context, tipifarnib has the potential to provide significant benefit to cancer patients with limited treatment options.
PTCL consists of a group of rare and usually aggressive forms of non-Hodgkin lymphoma that develop from mature T-cells. A prior Phase 2 trial of tipifarnib was sponsored by the National Cancer Institute and conducted at the Mayo Clinic and University of Iowa, in adult patients with relapsed or refractory lymphoma. The results of this study suggest that tipifarnib can be administered for prolonged periods and may produce durable responses as a single agent in relapsed lymphoma within a group of patients, who were heavily pretreated, including those with PTCL.
PCTL represents approximately 5-10% of non-Hodgkin’s lymphomas, or NHL, which corresponds to an annual incidence of approximately 5,000 patients in the United States.
Tipifarnib is currently being evaluated in a Phase 2 clinical trial for the treatment of patients with relapsed or refractory PTCL.